Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N, N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase

Molecular Cancer Therapeutics

Volumn 3, Issue 7, 2004, Pages 813-822

  Hector, Suzanne ^a   Porter, Carl W ^a   Kramer, Debora L ^a   Clark, Kimberly ^a   Prey, Joshua ^a   Kisiel, Nicholas ^a   Diegelman, Paula ^a   Chen, Ying ^a   Pendyala, Lakshmi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; CISPLATIN; MESSENGER RNA; N1,N11 DIETHYLNORSPERMINE; OXALIPLATIN; OXIDOREDUCTASE; POLYAMINE OXIDASE; SPERMIDINE; SPERMINE; SULFORHODAMINE B;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACETYLTRANSFERASES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG INTERACTIONS; FEMALE; GENE EXPRESSION; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYAMINES; RNA, MESSENGER; SPERMINE;

EID: 4444295545     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Mathe G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 1989;43:237-50.
2. Misset JL, Kidani Y, Gastiaburu J, et al. Oxalatoplatinum (1-OHP): experimental and clinical studies. In: Howell SB, editor. Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press; 1991. p. 369-75.
3. Wiseman LR, Adkins JC, Plosker GL, Goa K. Oxaliplatin. A review of its use in the management of metastatic colorectal cancer. Drugs Aging 1999;14:459-75.
4. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning and biotransformation of oxaliplatin. Cancer Res 1993;53:5970-6.
5. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 2001;48:398-406.
6. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin [Review] [100 refs]. Mol Cancer Ther 2002;1:227-35.
7. Di Francesco AM, Riccardi R. Cellular and molecular aspects of the drugs of the future. Cell Mol Life Sci 2002;59:1914-27.
8. Rixie O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel. Biochem Pharmacol 1996;52:1855-65.
9. Woynarowski JM, Chapman WG, Napier C, Herzig MS, Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 1998;54:770-7.
10. Woynarowski JM, Faivre S, Herzig MS, et al. Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000;58:920-7.
11. Hector S, Hawthorn L, Greco W, Pendyala L. Gene expression profiles after oxaliplatin treatment in A2780 ovarian carcinoma cells. Proc AACR 2002;43:62.
12. Porter C, Herrera-Omelas L, Pera P, Petrelli NF, Mittleman A. Polyamine biosynthetic activity in normal and neoplastic human colorectal tissues. Cancer 1987;60:1275-81.
13. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 2001;58:244-58.
14. 1-acetyltransferase in human lung cancer cells by the bis(ethyl)polyamine analogues. Cancer Res 1989;49:3829-33.
15. 1-acetyltransferase stably expressed in Chinese hamster ovary cells. J Biol Chem 1999;274:6175-82.
16. Chen Y, Kramer DL, Diegelman P, Vuicic S, Porter CW. Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res 2001;61:6437-44.
17. 1-acetyltransferase activity, polyamine pool depletion, and growth inhibition in human melanoma cell lines. Cancer Res 1991; 51:3715-20.
18. 11-diethylnorspermine in patients with non-small cell lung cancer. Clin Cancer Res 2002;8:684-90.
19. 11 diethylnorspermine in patients with advanced malignancy. Invest New Drugs 1997;15:227-34.
20. Vujcic S, Liang P, Diegelman P, Kramer DL, Porter CW. Genomic identification and biochemical characterization of the mammalian polyamine oxidase involved in polyamine back-conversion. Biochem J 2003;370:19-28.
21. Urdiales JL, Medina MA, Sanchez-Jimenez F. Polyamine metabolism revisited. Eur J Gastroenterol 2001;13:1015-9.
22. Vujcic S, Diegelman P, Bacchi CJ, Kramer DL, Porter CW. Identification and characterization of a novel flavin-containing spermine oxidase of mammalian cell origin. Biochem J 2002;367:665-75.
23. 1-acetylated polyamine oxidase. J Biol Chem 2003; 278:20514-25.
24. 1-acetyltransferase. Biochem J 2003; 373:661-7.
25. 1-acetyltransferase gene (exon/intron gene organization and localization to Xp22.1). Biochem Biophys Res Commun 1992;187:1493-502.
26. 1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. J Biol Chem 2000;275:38319-28.
27. 1-acetyltransferase. Mol Pharmacol 2003;64:1153-9.
28. Rubinstein LV, Shoemaker RH, Paull KD, et al. Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 1990;82:1113-8.
29. 1-acetyltransferase in MALME-3M human melanoma cells. J Biol Chem 1993;268:19118-25.
30. 1-acetyltransferase by polyamines. FEBS Lett 1996;391:89-94.
31. 1-acetyltransferase gene expression. Biochemistry 1996;35:14436-44.
32. Smith PF, Booker B, Pendyala L, et al. Pharmacokinetic modeling of oxaliplatin with and without 5-FU and radiation. Proc AACR 2001;42:542.
33. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review [Review] [49 refs]. Clin Cancer Res 2000;6:1205-18.
34. 1-acetyltransferase activity by novel spermine analogs. Mol Pharmacol 1997;52:69-74.
35. Seiler N. Functions of polyamine acetylation [Review] [114 refs]. Can J Physiol Pharmacol 1987;65:2024-35.
36. Maxwell P, Longley DB, Latif T, et al. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 2003; 63:4602-6.
37. 12-bis(ethyl -spermine, on polyamine metabolism and cell growth in human melanoma cell lines and melanocytes. Anticancer Res 1992;12:1083-9.
38. 1-acetyltransferase activity as a mechanism of cellular resistance to bis(ethyl)polyamine analogues. J Biol Chem 2000; 275:28708-14.
39. Kee K, Vujcic S, Kisiel N, Diegelman P, Kramer D, Porter CW. Activation of polyamine catabolism as a novel strategy for treating and/or preventing prostate cancer. Proc AACR 2003;44:1277.
40. 11-bisethylnorspermine with cis-diaminedichloroplatinum (II) against murine neoplastic cell lines in vitro and in vivo. Cancer Lett 1996; 99:99-107.
41. 12-bis(ethyl)spermine effect on growth of cis-diamminedichloroplatinum(II)-sensitive and -resistant human ovarian-carcinoma cell lines. Int J Cancer 1998;78:33-40.
42. Paliwal J, Janumpalli G, Basu HS. The mechanism of polyamine analog-induced enhancement of cisplatin cytotoxicity in the U-251 MG human malignant glioma cell line. Cancer Chemother Pharmacol 1998;41:398-402.
43. 12-bis(ethyl)spermine involves transcriptional and post-transcriptional regulation. Eur J Cancer 2001;37:281-9.